Atlas Trials

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

Clinical trial NCT06041646 · COMPLETED

Trial details

NCT number
NCT06041646
Sponsor
BioXcel Therapeutics Inc
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Bipolar DisorderSchizophreniaAgitation,PsychomotorSchizo Affective DisorderSchizophreniform Disorders
Start date
2023-10-02
Primary completion
2024-04-29
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.